PURE Bioscience (OTCMKTS:PURE) & Smith & Nephew SNATS (NYSE:SNN) Head-To-Head Review

PURE Bioscience (OTCMKTS:PURE) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Institutional & Insider Ownership

25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 35.6% of PURE Bioscience shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for PURE Bioscience and Smith & Nephew SNATS, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PURE Bioscience	0	0	0	0	0.00
Smith & Nephew SNATS	0	5	1	0	2.17

Smith & Nephew SNATS has a consensus price target of $30.93, suggesting a potential upside of 3.06%. Given Smith & Nephew SNATS’s stronger consensus rating and higher possible upside, analysts clearly believe Smith & Nephew SNATS is more favorable than PURE Bioscience.

Earnings & Valuation

This table compares PURE Bioscience and Smith & Nephew SNATS”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PURE Bioscience	$2.20 million	4.14	-$2.40 million	($0.03)	-2.33
Smith & Nephew SNATS	$6.16 billion	2.07	$625.00 million	N/A	N/A

Smith & Nephew SNATS has higher revenue and earnings than PURE Bioscience.

Profitability

This table compares PURE Bioscience and Smith & Nephew SNATS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PURE Bioscience	-109.59%	N/A	-321.74%
Smith & Nephew SNATS	N/A	N/A	N/A

Volatility & Risk

PURE Bioscience has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Summary

Smith & Nephew SNATS beats PURE Bioscience on 9 of the 11 factors compared between the two stocks.

About PURE Bioscience

PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.